Jürgen E Scholze

Summary

Affiliation: Humboldt University
Country: Germany

Publications

  1. ncbi Efficacy and safety of a fixed-dose combination of lercanidipine and enalapril in daily practice. A comparison of office, self-measured and ambulatory blood pressure
    Jurgen Scholze
    Centrum für Innere Medizin, Medizinische Poliklinik, Charite Campus Mitte, Luisenstr 11 13, 10117 Berlin, Germany
    Expert Opin Pharmacother 12:2771-9. 2011
  2. ncbi Optimal treatment of obesity-related hypertension: the Hypertension-Obesity-Sibutramine (HOS) study
    Jurgen Scholze
    Department of Medicine, Outpatient Clinic, CCM, Charite Universitatsmedizin Berlin, Luisenstrasse 11 13, 10117 Berlin, Germany
    Circulation 115:1991-8. 2007
  3. ncbi [Hypertension associated with obesity]
    J Scholze
    Campus Mitte/Medzinische Poliklinik,
    MMW Fortschr Med 148:39-41. 2006
  4. ncbi Initiation of hypertension treatment with a fixed-dose combination or its monocomponents -- does it really matter?
    J Scholze
    University Hospital Charité Campus Charité Mitte Outpatient Department, Berlin, Germany
    Int J Clin Pract 60:265-74. 2006
  5. ncbi [Cardiometabolic high risk patients with abdominal obesity. Frequency and risk factor profile in primary care]
    J Scholze
    , Medizinische Poliklinik
    MMW Fortschr Med 149:40. 2007
  6. ncbi [Therapy of obesity-associated hypertension]
    J Scholze
    Medizinische Poliklinik Center of Cardiovascular Research CCM
    Dtsch Med Wochenschr 130:2645-50. 2005
  7. ncbi [Pulse pressure in the therapeutic management of hypertension?]
    Jurgen Scholze
    Medizinische Poliklinik, Ambulante Spezialmedizin, Charite Universitatsmedizin Berlin, Campus Mitte, Berlin
    Herz 29:276-89. 2004
  8. ncbi [Cardiometabolic high risk patients with abdominal obesity. Frequency and risk factor profile in primary care]
    Jurgen Scholze
    Universitatsklinikum Charite, Campus Charite Mitte, Medizinische Poliklinik, Berlin
    MMW Fortschr Med 149:103-10. 2007
  9. ncbi [Differential therapy with calcium antagonists]
    Jürgen E Scholze
    Ambulante Spezialmedizin, Medizinische Universitätspoliklinik, Charité CCM, Berlin, Germany
    Herz 28:754-63. 2003
  10. ncbi [The ALLHAT study (antihypertensive and lipid-lowering treatment to prevent heart attack trial): primary antihypertensive agents - diuretics vs calcium channel blockers vs angiotensin-converting enzyme inhibitors]
    J Scholze
    Ambulante Spezialmedizin, Medizinische Poliklinik, , Germany
    Internist (Berl) 44:1193-5. 2003

Detail Information

Publications26

  1. ncbi Efficacy and safety of a fixed-dose combination of lercanidipine and enalapril in daily practice. A comparison of office, self-measured and ambulatory blood pressure
    Jurgen Scholze
    Centrum für Innere Medizin, Medizinische Poliklinik, Charite Campus Mitte, Luisenstr 11 13, 10117 Berlin, Germany
    Expert Opin Pharmacother 12:2771-9. 2011
    ..A fixed-dose combination (FDC) of enalapril and lercanidipine has been shown to be effective and safe in reducing blood pressure in randomized clinical trials. This study aims to determine effectiveness and safety in daily practice...
  2. ncbi Optimal treatment of obesity-related hypertension: the Hypertension-Obesity-Sibutramine (HOS) study
    Jurgen Scholze
    Department of Medicine, Outpatient Clinic, CCM, Charite Universitatsmedizin Berlin, Luisenstrasse 11 13, 10117 Berlin, Germany
    Circulation 115:1991-8. 2007
    ..To identify an optimal treatment regimen for obese hypertensive patients, we studied the interactions between a drug-based weight loss approach by sibutramine and different antihypertensive drug regimens...
  3. ncbi [Hypertension associated with obesity]
    J Scholze
    Campus Mitte/Medzinische Poliklinik,
    MMW Fortschr Med 148:39-41. 2006
  4. ncbi Initiation of hypertension treatment with a fixed-dose combination or its monocomponents -- does it really matter?
    J Scholze
    University Hospital Charité Campus Charité Mitte Outpatient Department, Berlin, Germany
    Int J Clin Pract 60:265-74. 2006
    ..It can be concluded that initiating antihypertensive treatment with a low fixed-dose combination of ramipril/felodipine ER is more effective and safe when compared with treatment with its monocomponents...
  5. ncbi [Cardiometabolic high risk patients with abdominal obesity. Frequency and risk factor profile in primary care]
    J Scholze
    , Medizinische Poliklinik
    MMW Fortschr Med 149:40. 2007
  6. ncbi [Therapy of obesity-associated hypertension]
    J Scholze
    Medizinische Poliklinik Center of Cardiovascular Research CCM
    Dtsch Med Wochenschr 130:2645-50. 2005
    ..Beta blockers should be used if definite cardiac indications are present...
  7. ncbi [Pulse pressure in the therapeutic management of hypertension?]
    Jurgen Scholze
    Medizinische Poliklinik, Ambulante Spezialmedizin, Charite Universitatsmedizin Berlin, Campus Mitte, Berlin
    Herz 29:276-89. 2004
    ....
  8. ncbi [Cardiometabolic high risk patients with abdominal obesity. Frequency and risk factor profile in primary care]
    Jurgen Scholze
    Universitatsklinikum Charite, Campus Charite Mitte, Medizinische Poliklinik, Berlin
    MMW Fortschr Med 149:103-10. 2007
    ....
  9. ncbi [Differential therapy with calcium antagonists]
    Jürgen E Scholze
    Ambulante Spezialmedizin, Medizinische Universitätspoliklinik, Charité CCM, Berlin, Germany
    Herz 28:754-63. 2003
    ....
  10. ncbi [The ALLHAT study (antihypertensive and lipid-lowering treatment to prevent heart attack trial): primary antihypertensive agents - diuretics vs calcium channel blockers vs angiotensin-converting enzyme inhibitors]
    J Scholze
    Ambulante Spezialmedizin, Medizinische Poliklinik, , Germany
    Internist (Berl) 44:1193-5. 2003
  11. ncbi Safety and efficacy of olmesartan: an observational pooled-analysis of 156,682 hypertensive patients
    Jurgen Scholze
    Centrum für Innere Medizin, Direktor Medizinische Poliklinik, Campus Mitte, Luisenstr 11 13, 10117 Berlin, Germany
    Expert Opin Drug Saf 10:185-96. 2011
    ..Angiotensin type 1 receptor blockers are recommended for first-line antihypertensive treatment...
  12. ncbi [Treatment of hypertension in obesity]
    J Scholze
    Medizinische Poliklinik, Campus Mitte, Charite, Berlin
    Herz 26:209-21. 2001
    ....
  13. ncbi [Isolated systolic hypertension. An independent disease]
    J Scholze
    Medizinische Poliklinik, Charite Universitatsmedizin Berlin, Luisenstr 11 13, 10117, Berlin
    Herz 35:568-74. 2010
    ..As a result of the available data from the results of treatment studies it appears that renin-angiotensin system (RAS) blockers and calcium channel blockers (CCBs) are the preferred drugs for treatment of this condition...
  14. ncbi [Sibutramine in clinical practice - a PMS-study with positive effects on blood pressure and metabolic parameters]
    J Scholze
    Ambulante Spezialmedizin, Medizinische Universitäts Poliklinik, Campus Charite Mitte, Berlin, Germany
    Dtsch Med Wochenschr 127:606-10. 2002
    ..As non-pharmacological therapies have failed to a large extent in the past, this post-marketing surveillance study was conducted to examine the feasibility, safety and efficacy of a medical weight reduction...
  15. ncbi [Pitfalls in hypertension management--misjudgements in diagnosis and therapy]
    J Scholze
    Medizinische Universitätspoliklinik Charité, Berlin, Germany
    Dtsch Med Wochenschr 127:2383-6. 2002
    ..These symptoms did not improve by changing her antihypertensive treatment. The patient's general condition was quite normal and there were no signs of acute or chronic cardiopulmonary decompensation...
  16. ncbi Epidemiological and economic burden of metabolic syndrome and its consequences in patients with hypertension in Germany, Spain and Italy; a prevalence-based model
    Jurgen Scholze
    Department of Medicine, Outpatient Clinic, CCM, Charite Universitatsmedizin Berlin, Luisenstrasse 11 13, 10117 Berlin, Germany
    BMC Public Health 10:529. 2010
    ..Our aim is to estimate the epidemiological and economic burden to the health service of metabolic syndrome in patients with hypertension in three European countries in 2008 and 2020...
  17. ncbi Influence of Sibutramine on blood pressure: evidence from placebo-controlled trials
    J Jordan
    Franz Volhard Clinical Research Center and HELIOS Klinikum, Medical Faculty of the Charite, Humboldt University, Berlin, Germany
    Int J Obes (Lond) 29:509-16. 2005
    ..Sibutramine, a serotonin and norepinephrine transporter inhibitor, is widely used as an adjunctive obesity treatment. There have been concerns that norepinephrine reuptake inhibition with sibutramine could exacerbate arterial hypertension...
  18. ncbi The effect of oral glucose loads on tissue metabolism during angiotensin II receptor and beta-receptor blockade in obese hypertensive subjects
    M Boschmann
    Franz-Volhard Clinical Research Center, , Berlin, Berlin, Germany
    Horm Metab Res 38:323-9. 2006
    ..The exact mechanism by which inhibition of the renin-angiotensin-aldosterone system decreases the diabetes risk remains unresolved and requires further study...
  19. ncbi Socio-economic status and the therapeutic effectiveness of antihypertensive treatment--the design of the LEO study
    A C Schmidt
    Charite Universitaetsmedizin, Department of Internal Medicine, Outpatient Clinic, Berlin, Germany
    Curr Med Res Opin 23:1987-95. 2007
    ..The angiotensin receptor blocker (ARB) olmesartan will be used to investigate the effectiveness of this drug in different socio-economic classes...
  20. ncbi Dissemination of a Sjögren's syndrome-associated extranodal marginal-zone B cell lymphoma: circulating lymphoma cells and invariant mutation pattern of nodal Ig heavy- and light-chain variable-region gene rearrangements
    A Hansen
    Dept of Medicine and Outpatient Department, Charite Universitatsmedizin Berlin, Schumannstrasse 20 21, 10098 Berlin, Germany
    Arthritis Rheum 54:127-37. 2006
    ..We undertook this study to analyze lymphoma progression and dissemination outside of the MALT-type lesions...
  21. ncbi [Multifocal nodular fatty infiltration of the liver associated with porphyria and haemochromatosis]
    U Daberkow
    Medizinische Poliklinik, Ambulante Spezialmedizin, Universitatsklinikum Charite, Campus Mitte, Berlin
    Dtsch Med Wochenschr 129:617-20. 2004
    ..Diabetes mellitus was diagnosed 22 years ago. Clinical evaluation revealed a mild obesity and a facial hypertrichosis...
  22. ncbi Comparison of immunoglobulin heavy chain rearrangements between peripheral and glandular B cells in a patient with primary Sjögren's syndrome
    A Hansen
    Department of Medicine, University Hospital Charite, Schumannstr 20 21, D 10098 Berlin, Germany
    Scand J Immunol 57:470-9. 2003
    ..Notably, one of the glandular clonal rearrangements (using VH1-08) was also detected in the patient's peripheral repertoire...
  23. ncbi Preactivated monocytes from hypertensive patients as a factor for atherosclerosis?
    Y Dörffel
    Outpatient Clinics of Internal Medicine, Charite, Medical Faculty, Humboldt University, Luisenstrasse 11 13, 10098 Berlin, Germany
    Atherosclerosis 157:151-60. 2001
    ..In monocytes, peak levels of PMA and Ang II induced CL analysis were significantly higher in patients (P<0.005). These data indicate that preactivated monocytes from hypertensives may be of pathogenic importance in atherosclerosis...
  24. ncbi Preactivated peripheral blood monocytes in patients with essential hypertension
    Y Dörffel
    Outpatient Clinics of Internal Medicine, Department of Rheumatology and Clinical Immunology, Charite University Hospital, Humboldt University, Berlin, Germany
    Hypertension 34:113-7. 1999
    ..Our results indicate preactivated peripheral blood monocytes in hypertensive patients. Ang II may be directly involved in the process of monocyte activation...
  25. ncbi [Blood pressure lowering and risk reduction under treatment with valsartan and its combination with hydrochlorothiazide (HCT)]
    J Scholze
    , Campus Mitte, Medizinische Poliklinik, Luisenstr. 11-13 D-ll117, Berlin
    MMW Fortschr Med 148:48. 2006
  26. ncbi Choice of drug treatment for obesity-related hypertension: where is the evidence?
    A M Sharma
    Franz Volhard Klinik, Max Delbruck Centre for Molecular Medicine, Berlin, Germany
    J Hypertens 19:667-74. 2001
    ....